First-in-human clinical trial underway to evaluate safety, tolerability and pharmacodynamic activity of HB2198 in normal healthy volunteers. A ...
A single-center real-world study compares the effectiveness and toxicity of chimeric antigen receptor T-cell therapy vs ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment ...
Please provide your email address to receive an email when new articles are posted on . Most patients with B-cell lymphomas who relapsed after CAR T-cell therapy responded to the novel, ...
AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both switchable and allogeneic CAR-T cell therapies, today announced that it has dosed the first patient ...
Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...
A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results